Safety of pyridostigmine in hypertensive patients receiving beta blockers

Michael Arad, Arie Roth, Julian Zelinger, Zehavit Zivner, Babeth Rabinowitz, Jacob Atsmon

نتاج البحث: نشر في مجلةمقالةمراجعة النظراء

9 اقتباسات (Scopus)

ملخص

In the last decade, pyridostigmine, a quaternary carbamate that reversibly inhibits the enzyme acetylcholinesterase, was proposed for pretreatment of nerve gas (organophosphate) poisoning. The objective of this study was to assess the cardiovascular effects of pyridostigmine in patients treated with β blockers. Eight hypertensive patients receiving regular treatment with β blockers were randomized in a double-blind crossover study to receive pyridostigmine (30 mg 3 times daily) or placebo for 2 days. Heart rate and blood pressure in the supine and standing positions were recorded every 2 hours during the day, and 24-hour Holter monitoring was performed. In addition, a symptom-limited exercise test was performed, and plasma catecholamine levels were determined at rest and at peak exercise. Pyridostigmine, as compared with placebo, did not induce any significant effect on heart rate, plasma catecholamine levels or resting blood pressure. Both systolic and diastolic blood pressures increased in accordance with exercise intensity (p < 0.01), although a significantly lower diastolic blood pressure was observed when pyridostigmine was used (average decrease 5 mm Hg compared with placebo; p < 0.01). No clinical adverse reactions were observed, confirming the relative safety of the combination of low-dose pyridostigmine with β-adrenergic blocking agents.

اللغة الأصليةالإنجليزيّة
الصفحات (من إلى)518-522
عدد الصفحات5
دوريةAmerican Journal of Cardiology
مستوى الصوت69
رقم الإصدار5
المعرِّفات الرقمية للأشياء
حالة النشرنُشِر - 15 فبراير 1992
منشور خارجيًانعم

بصمة

أدرس بدقة موضوعات البحث “Safety of pyridostigmine in hypertensive patients receiving beta blockers'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا